厄达替尼是用于治疗晚期或转移性尿路上皮癌的药物

Balversa is a small molecule inhibitor of the fibroblast growth factor receptor (FGFR) approved for the treatment of cancer and marketed as Balversa. FGFR is a subset of tyrosine kinases that are unregulated in some tumors and affect tumor cell differentiation, proliferation, angiogenesis, and cell survival. Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further development.

In March 2018, Balversa (erdafitinib) was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of urothelial cancer.

In April 2019, erdafitinib Balversa (erdafitinib) was approved by the FDA for the treatment of metastatic or locally advanced bladder cancer with FGFR3 or FGFR2 alterations, which has surpassed traditional platinum-based therapies, but has yet to be confirmed in trials. The U.S. Food and Drug Administration (FDA) considers it a first-in-class drug.

Precautions for taking Balversa: (1) Eye diseases: Erdafitinib can cause central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED). Have eye exams monthly for the first four months of treatment, every 3 months thereafter, and any time visual symptoms occur. Withhold Balversa if CSR/RPED occurs and permanently discontinue if there is no response within 4 weeks or if the severity reaches Grade 4. (2) Hyperphosphatemia: The increase in blood phosphorus levels is caused by the pharmacodynamic effects of erdafitinib Balversa. Monitor serum phosphorus levels and adjust treatment dosage as needed. (3) Embryo-fetal toxicity: Can cause fetal harm. Inform patients of the potential risk to the fetus and use effective contraception.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: